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Abstract
The development of the embryonic mammary gland involves
communication between the epidermis and mesenchyme and is
coordinated temporally and spatially by various signaling pathways.
Although many more genes are likely to control mammary gland
development, functional roles have been identified for Wnt,
fibroblast growth factor, and parathyroid hormone-related protein
signaling. This review describes what is known about the molecular
mechanisms that regulate embryonic mammary gland development.
Introduction
Over the past several years excellent progress has been
made in beginning to define the signaling pathways that are
involved in the very earliest stages of mammary development.
In this review we describe embryonic morphogenesis in
general terms and review recent developments regarding the
molecular signaling involved at each stage of fetal mammary
development. Our discussion is limited to the mouse, which
has become the experimental model of choice.
Overview of morphogenesis
For the purposes of discussion, embryonic mammary gland
development can be divided into a series of specific develop-
mental stages [1-3]. The initiating event is the formation of
bilateral milk lines running between the fore and hind limbs on
embryonic day (E) 10.5 in the mouse. Epidermal cells within
the milk line become columnar and multilayered, defining a
ridge that protrudes above and below the plane of the single-
layered primitive epidermis or periderm.
The second stage occurs by E11.5, when five pairs of lens-
shaped placodes form at specific locations along the
mammary line. Placodes are thought to arise from the
migration of cells within the mammary line, although this has
yet to be formally documented. Individual placodes form in a
characteristic sequence; pair 3 is first, followed by pairs 4, 1
and 5, and finally by pair 2.
The third stage involves the invagination of cells within the
placode into the underlying mesenchyme to form the typical
bulb-shaped mammary buds and occurs between E11.5 and
E12.5 (Fig. 1). Part of this process involves the condensation
and differentiation of the underlying mesenchyme into
specialized, dense mammary mesenchyme arrayed radially
around the epithelial bud. Differentiation of the dense
mesenchyme is associated with expression of the androgen
receptor, and in many mouse strains fetal androgens lead to
the destruction of the mammary anlage in male embryos [2]
(Fig. 1c). In female embryos the buds remain morphologically
quiescent until the final stages of embryonic development
begin at E15.5–E16.5. At this point, the mammary epithelial
cells begin to proliferate, and the bud sprouts down out of
the dense mesenchyme and into the developing mammary fat
pad located within the dermis. Concurrent with this process,
epidermal cells overlying the bud differentiate into nipple skin.
Once the mammary sprout has reached the fat pad it begins
a process of ductal branching morphogenesis that gives rise
to the rudimentary ductal tree, consisting of a primary duct
and 15–20 secondary branches, which is present at birth
(Fig. 1d,e).
Specification of the milk line
Although the presence of the mammary line in mice had
previously been questioned, recent studies have provided
morphologic and molecular evidence of this structure [3-6].
Specification of the mammary line is dependant on canonical
Wnt signaling [4]. One of the earliest described markers of
the mammary line is the expression of a Wnt responsive β-
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galactosidase (TOPGAL) transgene in cells between the limb
buds of E10.5 TOPGAL transgenic embryos. Following this,
several Wnt genes become expressed within the mammary
line between E11.25 and E11.5 (40–42 somite stage),
including Wnt10b, Wnt10a, and Wnt6 [4-6]. Disruption of
Wnt signaling within the developing epidermis through
transgenic expression of the secreted Wnt inhibitor DKK1
has been shown to extinguish TOPGAL transgene expression
and all evidence of the mammary line, including the
expression of the Wnt genes mentioned above [4]. These
findings suggest that specification of the mammary line
requires an early Wnt signaling event that is then responsible
for inducing a cascade of further Wnt gene expression and
Wnt signaling within the milk line and placodes [4-6]. At this
time it is not known which Wnt genes, receptors, or T cell
factor family members are involved in this earliest
specification of Wnt signaling. Chu and coworkers [4]
demonstrated that several Wnts, including Wnt3, Wnt10b
and Wnt6, are expressed at low levels throughout the
epidermis at E10.5, qualifying them as candidates to mediate
this function.
The fibroblast growth factor (FGF) signaling pathway also
may contribute to mammary line specification. Knockout of
the FGF10 and FGFR2b genes in mice has been shown to
disrupt the formation of four out of the five mammary
placodes (numbers 1, 2, 3, and 5) [7]. Between E10.5 and
E11.5, Fgf10 is expressed in the most ventral-lateral reaches
of the dermatomyotome of the somites adjacent to the
developing mammary line [7]. FGFR2b is expressed within
the mammary epithelial placodes, although it has not been
identified specifically within the mammary line [7]. Eblaghie
and colleagues [5] showed that another FGF receptor
(FGFR1b) and four potential ligands, namely Fgf4, Fgf8,
Fgf9, and Fgf17, are expressed within the mammary
placodes. Unfortunately, those investigators did not report on
the pattern of expression of these molecules at earlier time
points during the formation of the mammary line. They did
demonstrate that a chemical inhibitor of FGFR1 signaling
inhibited the expression of the TBX3 gene (see below) in the
mammary line and placodes in cultured embryos, although at
the doses used in this study the inhibitor may not have been
completely specific for this receptor. It also has been shown
that inhibition of Wnt signaling does not alter expression of
Fgf10 or FGFR1 signaling [4,5]. These data all suggest that
FGF signaling is important to the earliest stages of mammary
development and acts in parallel to Wnt signaling, rather than
downstream of it.
Mammary gland aplasia or hypoplasia is a prominent feature
of the mammary-ulnar syndrome, caused by mutations in the
TBX3 gene, which encodes a T-box transcription factor [8,9].
TBX3–/– mice exhibit no morphologic evidence of mammary
placodes and do not show evidence of Wnt10b or lymphoid
Figure 1
Embryonic mammary development. (a) Embryonic day (E)12.5. The epithelial cells have invaginated to form the initial bud, but the dense mammary
mesenchyme has not yet formed. (b) Female bud at E14.5. The bud is fully formed. The epithelial cells are arrayed in a ball-on-stalk, or inverted
bulb shape. The mesenchymal cells are arranged in four to five layers in a radial fashion around the epithelial cells. (c) Male bud at E14.5. Under
the influence of testosterone, the mesenchymal cells condense around the stalk of the bud (arrowheads), constricting it until the connection with
the surface epidermis is severed. After this occurs mammary mesenchyme cells and many epithelial cells undergo apoptosis. (d) Mammary sprout
at E18.5. The epithelial bud has grown out from the mammary mesenchyme into the lower dermis, where it will enter the mammary fat pad and
begin a period of active ductal branching morphogenesis. (e) A whole mount of the initial primary duct system from a 2-day-old mouse, the end-
result of embryonic mammary morphogenesis. The arrowhead denotes the connection of the primary duct to the skin.222
Breast Cancer Research    October 2005 Vol 7 No 5 Hens and Wysolmerski
enhancing factor (Lef)1 expression, two molecular markers of
mammary placodes [9]. So, it is evident that TBX3 is
important for placode formation. However, Eblaghie and
coworkers [5] recently showed that TBX3 is expressed in the
mammary line beginning at E10.25, raising the question of
whether TBX3 might participate in the specification of the line
itself. Consistent with this idea, TBX3 expression was
induced by both FGF and Wnt signaling within the mammary
line of cultured mouse embryos [5].
A working model that integrates these findings is shown in
Fig. 2. Specification of the mammary line would be the result
of FGF signals from the somite acting in concert with
canonical Wnt signaling initiated by generally expressed
Wnts in the ectoderm. This dual signal would activate TBX3
expression, which would in turn activate or amplify the
expression of other Wnt and FGF pathway genes necessary
for full mammary line development and the transition to
placode formation. In this manner TBX3 would be both
downstream and upstream of Wnt and FGF signaling, which
is a known paradigm for T-box transcription factors.
Placode formation
The same signaling pathways that have been implicated in
the specification of the mammary line are also important for
the development of the mammary placodes. TOPGAL
transgene expression and Wnt10b expression have been
reported to become discontinuous within the mammary line
and localize to the forming placodes [4-6]. The placodes are
thought to form from cell movements within the mammary
line, and in TOPGAL embryos individual ‘wandering’ β-
galactosidase positive cells can be seen clustering around
the developing placodes [4]. In cultured embryos, activation
of Wnt signaling using lithium chloride or Wnt3a results in
the accelerated formation of enlarged mammary placodes [4].
Finally, Lef1–/– embryos form smaller placodes that then
degenerate [3,10]. Wnt signaling is known to modulate cell
adhesion and promote cell migration in other settings, and so
it is attractive to speculate that Wnts might be involved in
promoting the cell migration and invagination necessary for
the formation of placodes.
As noted in the section above, the Fgf receptor FGFR2b is
expressed within the developing mammary placodes, and
disruption of this gene in mice inhibits the development of four
pairs of placodes [7]. In addition, Fgf4, Fgf8, Fgf9, and Fgf17
are all expressed within the developing placodes, as is another
Fgf receptor, FGFR1 [5]. In cultured embryos, beads soaked
with Fgf8 have been shown to induce the ectopic expression of
placodal markers when placed along the mammary line, and an
FGFR1 inhibitor has been shown to inhibit the development of
placodes from the mammary line [5]. Thus, it is likely that FGF
signaling participates in regulating this process.
TBX3 and the related T-box family member TBX2 are both
expressed at E11.5 in developing placodes [9]. As noted in the
section above, mice lacking TBX3 fail to develop mammary
placodes 1, 3, 4, and 5, and fail to express the placodal
markers Wnt10b and Lef-1 [9]. Very little is known about the
function of TBX2 in the mammary gland, but the phenotype of
the TBX3 knockout mice suggests that TBX2 and TBX3 have
nonoverlapping functions. Interestingly, TBX2 has been shown
to regulate adhesion molecules such as cadherins and
integrins [11], and so it is attractive to speculate that it may
contribute to the migration and invagination of the mammary
epithelial cells during placode formation.
Ectodysplasin (Eda) is a member of the tumor necrosis factor
ligand superfamily [12]. Mice deficient in Eda (Tabby mice) or
in its receptor (Edar) have defects in several epidermal
appendages, including the mammary gland [13]. Eda is
expressed in the underlying mesenchyme, whereas Edar is
located in the epithelial cells of the mammary placode [12].
Transgenic mice overexpressing Eda-A in embryonic skin
form enlarged and supernumerary mammary placodes along
the mammary line [12]. These results suggest that Edar
signaling promotes placode formation and/or directs the
positioning of the placode along the mammary line. However,
ectopic placodes only form along the mammary line,
suggesting that the actions of Eda/Edar are downstream of
the specification of this structure.
Figure 2
A model of mammary line specification and placode formation.
Fibroblast growth factor (Fgf)10 from the ventrolateral portion of the
somites acts in concert with Wnts expressed within the epidermis to
specify the mammary line. This induces TBX3 expression, which in turn
induces the expression of specific Wnts and Fgfs within the mammary
line. These molecules act in an autocrine fashion and cooperate with
other signaling pathways to form 10 pairs of placodes at specific
locations along the original mammary line.223
Bud formation
A growing number of signaling molecules have been
described as being expressed within either the epithelial or
mesenchymal cells of the mammary bud (Table 1). However,
functional information exists for only a few of these signaling
pathways. As with the previous stages, Wnt signaling
appears to participate in the formation of the mammary buds.
Wnt reporter (TOPGAL) gene expression remains induced in
the epithelial cells of the mammary bud through to E15 [4]. In
addition, many Wnt pathway genes are expressed within the
mammary buds at E12.5 and E15 [4]. Lef1 is expressed in
the mammary placode and bud at E11/12, and later, at
around E14.5, it is expressed in the condensed mammary
mesenchyme [14]. As noted in the section above, Lef1–/–
mice form small placodes, which degenerate instead of going
on to form mammary buds [3,10]. Whether this represents a
failure of placode development or a block in the transition
from placode to bud is not clear, because a detailed study of
molecular markers of mammary development has not been
done on these embryos. Furthermore, it is not clear whether
the mammary defects in Lef1–/– mice are the result of the loss
of Lef1 from epithelium or mesenchyme, or both.
The homeodomain-containing transcription factors MSX1 and
MSX2 are both expressed in the mammary buds, and MSX2
is also expressed in the underlying mesenchyme [15,16].
Knockout of either MSX1 or MSX2 alone has no effects on
mammary bud formation, although knockout of MSX2 does
affect the next phase of mammary development. However,
when both genes are disrupted placodes form but do not
develop into mammary buds [16]. Thus, MSX1 and MSX2
appear to have necessary but redundant functions during the
formation of the buds.
One of the molecules expressed by the mammary epithelial
bud as it starts to invaginate into the mesenchyme is
parathyroid hormone-related protein (PTHrP). Its receptor,
PTH1R, is expressed in the mesenchyme underlying the
developing bud [14,17]. If either PTHrP or the PTH1R is
disrupted in mice, then morphologically normal mammary buds
form but they degenerate and never grow out to form ductal
trees [14,17]. This is because PTHrP is necessary for the
mesenchyme to acquire a specialized mammary fate. When
this does not occur, the mammary epithelial cells take on an
epidermal fate, undergo squamous differentiation and
morphogenesis fails. Another consequence is the loss of
sexual dimorphism, because PTHrP is the epithelial factor that
induces androgen receptor expression within the mammary
mesenchyme [18]. PTHrP signaling is also necessary for the
mammary mesenchyme to induce the overlying epidermis to
form the nipple. Thus, in PTHrP and PTH1R knockout mice no
nipples are formed, and when PTHrP is overexpressed in the
epidermis the entire ventral surface of the embryo is
transformed into nipple skin [14,17,18].
Rudimentary ductal tree
Although we know about several hormones and paracrine
factors that regulate postnatal mammary ductal growth
[19,20], we know very little about the mechanisms that are
involved in the formation of the rudimentary ductal tree from
the mammary buds. The initial branching morphogenesis of
the embryonic mammary gland is hormone independent
because mice that are deficient in either estrogen receptor (α
or β), the prolactin receptor, the growth hormone receptor, or
the progesterone receptor have no obvious embryonic
mammary phenotype [19,20]. Likewise, the initial outgrowth
of the bud occurs in the absence of growth factor receptors
such as the insulin-like growth factor-1 receptor and the
epidermal growth factor receptor, which are though to be
important to the regulation of hormone dependant branching
morphogenesis during puberty [20]. Four genetic models
develop mammary buds but subsequently have defects in
ductal outgrowth. These are PTHrP–/–, PTH1R–/–, MSX2–/–
and RhoGAP p190B–/– mice [16,17,21]. In the case of
PTHrP and its receptor, the failure of bud outgrowth is the
result of defects in the mammary mesenchyme [14,17,18]. A
similar mesenchymal defect might also hold for the MSX2–/–
mice, because expression of this transcription factor is limited
to the mesenchyme at this stage [15,16]. The mechanisms
underlying the failure of transplanted RhoGAPp190B–/– buds
to grow are currently under investigation [21]. At this point,
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Table 1
Signaling molecules localized to mammary buds
Epithelium Mesenchyme
PTHrP PTH1R
Wnts 10a, 10b, 6 Eda-A1
β-Catenin Wnt11, Wnt5a
Axin2 Lef1
Lef1 β-Catenin
Kremen 2 Fgf7
FGFR2b, FGFR1b MSX2
Fgfs 4,8,9,17 TBX2
Sonic Hedgehog, Indian Hedgehog Hoxa9, Hoxb9, Hoxc9
Gli2, Gli3, Ptc1 BMP4
BMP2 ER-α, ER-β
Edar Androgen receptor
MSX1, MSX2 Pdgfr
Irx2 Tenascin C
Lmx1b
TBX3
PdgfA
Edar, ectodysplasin receptor; FGF, fibroblast growth factor; Lef,
lymphoid enhancing factor; Pdgfr, platelet-derived growth factor
receptor; PTH1R, PTHrP receptor 1; PTHrP, parathyroid hormone-
related protein.224
we have very little idea as to what regulates the initial phase
of ductal growth. This is an area ripe for investigation and one
wonders whether the mechanisms at play here might shed
light on the acquisition of hormone independent growth by
breast cancers.
Conclusion
Embryonic mammary gland development requires the
coordination of many signaling pathways to direct the cell
shape changes, cell movements, and cell–cell interactions
necessary for proper morphogenesis. Many of the processes
that are necessary for development are recapitulated in
breast cancer, especially in the metastatic cascade [22].
Although much progress has been made in the past several
years, we remain in the early stages of our understanding of
the specific molecular pathways that mediate the
development of the embryonic gland. Our hope is that a
better understanding of development will inform efforts to
understand and eradicate metastatic breast cancer.
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